Brought to you by 
AcelRx partners anesthesia drug/device Zalviso with Grunenthal in Europe, Australia
07 Dec 2015
Executive Summary
AcelRx Pharmaceuticals Inc. granted fellow pain management company Grunenthal GMBH rights to sell its patient-controlled anesthesia (PCA) drug/device Zalviso (sufentanil; ARX01; ARXF01) in the European Union, European Economic Area, and Australia.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AcelRx partners anesthesia drug/device Zalviso with Grunenthal in Europe, Australia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice